search
Back to results

Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome

Primary Purpose

Osteoarthritis of the Shoulder, Shoulder Pain, Pain, Postoperative

Status
Withdrawn
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Bupivacaine Liposome Injection
Standard Therapy
Sponsored by
University of Massachusetts, Worcester
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Osteoarthritis of the Shoulder focused on measuring Exparel, Bupivacaine Liposome, Total Shoulder Replacement, Pain Management

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Adult subjects older than 18years old undergoing Total Shoulder Replacement (TSR) or reverse TSR surgery.
  2. Meet criteria for regional nerve block.
  3. Weight greater than 60kg (safety to keep liposomal bupivacaine and bupivacaine dosing below 3mg/kg).

Exclusion Criteria:

  1. Recent drug use
  2. Subjects on chronic buprenorphine therapy (either for opioid replacement or pain control).
  3. Nerve injury (cervical stenosis, trauma, etc) of the surgical limb.
  4. Coagulopathy
  5. Subjects with significant liver disease (as amide type local anesthetics such as bupivacaine are metabolized by the liver).
  6. Infection near or in the area of the nerve block.
  7. Subject refusal of regional anesthesia.
  8. Vulnerable populations (prisoners, mental impairment / dementia, etc).
  9. Subjects requiring interpreter services (not proficient in English).
  10. Subjects with poor cardio-pulmonary reserve who might not tolerate a hemi-diaphragmatic paralysis or hemi-diaphragmatic paresis.

Sites / Locations

  • UMASS Memorial Medical Center

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Bupivacaine Liposome

Standard therapy

Arm Description

Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist). Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%

Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist). Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000.

Outcomes

Primary Outcome Measures

Morphine Equivalent Dose of Opioids
Morphine equivalent dose (MED) of opioids within the first 24 hours after surgery (including PACU and medications on the floor)

Secondary Outcome Measures

Morphine equivalent dose of opioids
Morphine equivalent dose (MED) of opioids within the first 24-48 hours after surgery (including PACU and medications on the floor)
Visual Analogue Scale Pain Score
Visual Analogue Scale Pain Score (VAS) in the first 24 hours, and 24-48 hours after surgery
Hospital Length of Stay
Hospital Length of Stay
Post-Operative Brief Pain Inventory Short Form
Brief Pain Inventory Short Form pre-operatively on POD 0, POD 1, and POD 2
Cost Analysis
Cost estimate of each technique
Opioid Administration
Time to administration of the first opioid

Full Information

First Posted
October 2, 2019
Last Updated
June 30, 2022
Sponsor
University of Massachusetts, Worcester
search

1. Study Identification

Unique Protocol Identification Number
NCT04134442
Brief Title
Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
Official Title
Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome
Study Type
Interventional

2. Study Status

Record Verification Date
June 2022
Overall Recruitment Status
Withdrawn
Why Stopped
A new large meta-analysis was published. The results showed the likelihood that liposomal bupivacaine and nerve blocks no longer offer significant contribution. Decision was made to terminate the study.
Study Start Date
December 9, 2019 (Actual)
Primary Completion Date
September 23, 2021 (Actual)
Study Completion Date
September 23, 2021 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Massachusetts, Worcester

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
Yes

5. Study Description

Brief Summary
To improve pain control and decrease opioid requirements for subjects undergoing Total Shoulder Replacement.
Detailed Description
For the pilot study the investigators will use a total of 20 cases per group. A HIPAA Waiver will be used for screening purposes. The investigators will be using the electronic medical record system (EPIC) to screen for subjects in the University of Massachusetts Medical (UMass) system. Subjects will be recruited and consented as described later in the study plan. Subjects will be randomized to the two groups (standard therapy or BL) using a random number generator. The random number with the type of anesthetic will stored in envelopes and will be opened in sequence on each day of the interscalene nerve block (ISNB). Group 1: Standard therapy Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist) Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000. Group 2: BL Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist) Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33% In accordance with our current practice, all subjects will have premedication with midazolam and fentanyl and general anesthesia (GA) with endotracheal tube (ETT). Propofol will be used for induction of GA. During surgery, administration of short acting narcotics (fentanyl) will be at the discretion of the anesthesia team. As BL will be used, no additional local anesthetics will be used during surgery (i.e. lidocaine for induction or maintenance of anesthesia, or local anesthetics for infiltration in the surgical field). Ketamine will not be used as an anesthetic / analgesic adjunct After this, all patients will remain on our standard protocols. In the PACU, subjects will receive IV hydromorphone for pain control. Once on the post- operative floor, subjects pain will be managed with oxycodone as needed every 4 hours (5mg for moderate pain, 10mg for severe pain) and 0.4 mg IV hydromorphone for breakthrough pain. Subject's postoperative opioid consumption and pain scores will be obtained from their charts. Subjects will fill out a Brief Pain Inventory Short Form pre-operatively, on post-operatively day (POD) 1, and POD 2 (if the patients have not been discharged from the hospital). Blinding In this study, the investigators will work with the Investigational Drug Pharmacy, who will store the medications, and supply medications on the day of surgery. Subjects will be blinded, as all subjects will receive an ISNB. The surgeon, anesthesiology team, post-anesthesia care unit (PACU) and floor nurses will also be unaware of group assignment, and will use their clinical judgement and subjects' reporting when administering medications and recording pain scores. Surveys about subjects' satisfaction with pain control, as well as data collection from subjects' records will be done by study investigators that are not involved in performing injections. The Anesthesiologists performing the nerve block will not be blinded (as the Bupivacaine Liposome solution is a suspension and is white, whereas bupivacaine solution is clear), but will not participate in further evaluations of the subjects or data collection.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Osteoarthritis of the Shoulder, Shoulder Pain, Pain, Postoperative
Keywords
Exparel, Bupivacaine Liposome, Total Shoulder Replacement, Pain Management

7. Study Design

Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
0 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Bupivacaine Liposome
Arm Type
Experimental
Arm Description
Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist). Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%
Arm Title
Standard therapy
Arm Type
Active Comparator
Arm Description
Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist). Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000.
Intervention Type
Drug
Intervention Name(s)
Bupivacaine Liposome Injection
Other Intervention Name(s)
Standard Therapy and Bupivacaine Liposome 10ml 1.33%
Intervention Description
Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, age, or current therapy as currently determined by APS anesthesiologist) Pre-operative ultrasound guided ISNB with a 20ml mixture consisting of 10ml of 0.5% bupivacaine with epinephrine 1:200,000, and 10ml of BL 1.33%
Intervention Type
Other
Intervention Name(s)
Standard Therapy
Intervention Description
Standard pre-operative and post-operative medical regimen including standing acetaminophen 650mg q6hours, gabapentin 300mg q8hours and as needed oxycodone every 4 hours (unless there are contraindications due to liver function, kidney function, or age as currently determined by acute pain service (APS) anesthesiologist) Preoperative, ultrasound guided ISNB with a bupivacaine mixture: 20ml 0.5% bupivacaine and epinephrine 1:200,000.
Primary Outcome Measure Information:
Title
Morphine Equivalent Dose of Opioids
Description
Morphine equivalent dose (MED) of opioids within the first 24 hours after surgery (including PACU and medications on the floor)
Time Frame
First 24 hours
Secondary Outcome Measure Information:
Title
Morphine equivalent dose of opioids
Description
Morphine equivalent dose (MED) of opioids within the first 24-48 hours after surgery (including PACU and medications on the floor)
Time Frame
24-48 hours
Title
Visual Analogue Scale Pain Score
Description
Visual Analogue Scale Pain Score (VAS) in the first 24 hours, and 24-48 hours after surgery
Time Frame
24-48 hours
Title
Hospital Length of Stay
Description
Hospital Length of Stay
Time Frame
Through study completion, an average of 2-3 days
Title
Post-Operative Brief Pain Inventory Short Form
Description
Brief Pain Inventory Short Form pre-operatively on POD 0, POD 1, and POD 2
Time Frame
<1 day, 1 day, and 2 days
Title
Cost Analysis
Description
Cost estimate of each technique
Time Frame
Through study completion, an average of 2-3 days
Title
Opioid Administration
Description
Time to administration of the first opioid
Time Frame
Up to 72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Adult subjects older than 18years old undergoing Total Shoulder Replacement (TSR) or reverse TSR surgery. Meet criteria for regional nerve block. Weight greater than 60kg (safety to keep liposomal bupivacaine and bupivacaine dosing below 3mg/kg). Exclusion Criteria: Recent drug use Subjects on chronic buprenorphine therapy (either for opioid replacement or pain control). Nerve injury (cervical stenosis, trauma, etc) of the surgical limb. Coagulopathy Subjects with significant liver disease (as amide type local anesthetics such as bupivacaine are metabolized by the liver). Infection near or in the area of the nerve block. Subject refusal of regional anesthesia. Vulnerable populations (prisoners, mental impairment / dementia, etc). Subjects requiring interpreter services (not proficient in English). Subjects with poor cardio-pulmonary reserve who might not tolerate a hemi-diaphragmatic paralysis or hemi-diaphragmatic paresis.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Alexander Chan, MD
Organizational Affiliation
University of Massachusetts Chan Medical School
Official's Role
Principal Investigator
Facility Information:
Facility Name
UMASS Memorial Medical Center
City
Worcester
State/Province
Massachusetts
ZIP/Postal Code
01655
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Improving Pain Management After Total Shoulder Replacement Using Bupivacaine Liposome

We'll reach out to this number within 24 hrs